{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:54:16Z","timestamp":1781585656105,"version":"3.54.5"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Both fruquintinib and TAS\u2010102 monotherapies are guideline\u2010recommended for third\u2010line treatment of metastatic colorectal cancer (mCRC). This study aimed to analyze the preliminary outcomes of fruquintinib combined with TAS\u2010102, with or without stereotactic body radiation therapy (SBRT), as a third\u2010 or later\u2010line therapy for mCRC. This prospective, two\u2010arm, phase II study planned to enroll 66 patients with mCRC who were unresponsive to at least two prior lines of therapy. Patients were allocated to either the FTS (fruquintinib + TAS\u2010102\u2009+\u2009SBRT) or FT (fruquintinib + TAS\u2010102) group. Eligible patients received fruquintinib (4\u2009mg, qd, days 1\u201321) and TAS\u2010102 (30\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    , bid, days 1\u20135; 15\u201319) orally every 4\u2009weeks until disease progression or intolerable toxicity. The primary endpoint was progression\u2010free survival (PFS, per RECIST 1.1); secondary endpoints included overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs, graded using CTCAE v5.0). By January 20, 2025, 40 patients were enrolled (FTS group, 11; FT group, 29), with a median follow\u2010up of 8.48\u2009months. In 20 (50%) patients, the number of metastatic organs was \u2265\u20093. However, the number of metastatic lesions was &gt;\u20095 in 32 (80%) patients. For the 36 eligible patients, the ORR and DCR were 19.4% and 88.9%, respectively. The median PFS was 8.58\u2009months; however, the median OS has not been attained. The most common treatment\u2010related AE was decreased white blood cell count (92.5%); grade 3\u20134 AEs included decreased lymphocyte count (12.5%). No treatment\u2010related death occurred. Fruquintinib combined with TAS\u2010102, with or without SBRT, showed promising preliminary efficacy and acceptable safety as third\u2010 or later\u2010line treatment of mCRC.\n                  <\/jats:p>","DOI":"10.1002\/cam4.71884","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:47:07Z","timestamp":1777524427000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fruquintinib Plus\n                    <scp>TAS<\/scp>\n                    \u2010102 With or Without\n                    <scp>SBRT<\/scp>\n                    as Third\u2010 Or Later\u2010Line Therapy for Metastatic Colorectal Cancer: Preliminary Results From a Prospective Phase\n                    <scp>II<\/scp>\n                    Trial"],"prefix":"10.1002","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6878-4898","authenticated-orcid":false,"given":"Yi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfen","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linchun","family":"Liang","sequence":"additional","affiliation":[{"name":"Oncology Department Ningbo Mingzhou Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunjie","family":"Chen","sequence":"additional","affiliation":[{"name":"Hepatopancreatobiliary Surgery Department 2 Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leizheng","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery Ningbo Medical Center, Lihuili Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology Radiotherapy and Chemotherapy The Affiliated Lihuili Hospital of Ningbo University  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology Ningbo Medical Center, Lihuili Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ren","sequence":"additional","affiliation":[{"name":"Hepatopancreatobiliary Surgery Department 2 Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiochemotherapy The Affiliated People's Hospital of Ningbo University  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Radiochemotherapy The Affiliated People's Hospital of Ningbo University  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6390-8938","authenticated-orcid":false,"given":"Qingsong","family":"Tao","sequence":"additional","affiliation":[{"name":"The Chemoradiotherapy Center The First Affiliated Hospital of Ningbo University  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology Radiotherapy and Chemotherapy The Affiliated Lihuili Hospital of Ningbo University  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Ye","sequence":"additional","affiliation":[{"name":"Gastrointestinal Hernia Surgery Department Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiochemotherapy The Affiliated People's Hospital of Ningbo University  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0227-7883","authenticated-orcid":false,"given":"Yunbao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoxun","family":"Mao","sequence":"additional","affiliation":[{"name":"Department of Anorectal Surgery Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9473-1629","authenticated-orcid":false,"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuangzhou","family":"Rao","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Chemotherapy Ningbo No. 2 Hospital  Ningbo China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,4,29]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70156-7"},{"key":"e_1_2_12_4_1","first-page":"41","article-title":"FRESCO\u20102 Study Investigators. Fruquintinib Versus Placebo in Patients With Refractory Metastatic Colorectal Cancer (FRESCO\u20102)","volume":"402","author":"Dasari A.","year":"2023","journal-title":"An International, Multicentre, Randomised, Double\u2010Blind, Phase 3 Research: Lancet"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414325"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214963"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.7855"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2011.244"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30827-7"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0643"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000528867"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00290"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.08.038"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104819"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2021.09.027"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61900-X"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.3245"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.4161\/15384047.2014.964087"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.4675"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26611"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33546"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70510-7"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.3536"},{"issue":"4","key":"e_1_2_12_24_1","article-title":"Exploratory Study of TAS\u2010102 Combined With Intermittent Administration of Fruquintinib in the Treatment of Third\u2010Line Metastatic Colorectal Cancer","volume":"43","author":"Niu J. Y.","year":"2025","journal-title":"ASCO Gastrointestinal Cancers Symposium"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-24-559"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71884","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T04:19:01Z","timestamp":1781583541000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,29]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["10.1002\/cam4.71884"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71884","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,29]]},"assertion":[{"value":"2025-11-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71884"}}